Description

With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor

With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticles, immunomodulatory agents and complex viral–particle ligands along with manipulations of the tumor microenvironment.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2017-11-08
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.2147/OV.S145262
    • Identifier Type
      International standard serial number
      Identifier Value
      2253-1572
    Note

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Yokoda, R., Nagalo, B., Vernon, B., Oklu, R., Albadawi, H., Deleon, T., . . . Borad, M. (2017). Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic Virotherapy, Volume 6, 39-49. doi:10.2147/ov.s145262

    Machine-readable links